Ivonescimab combined with chemotherapy showed significant progression-free survival benefits in advanced squamous NSCLC patients, including both PD-L1-positive and PD-L1-negative populations. The ...

The median overall survival from the date of progression was 12.19 months for patients who continued on pembrolizumab-based therapy and 4.44 months for patients who did not. Patients with ...